AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA

Their core work

AOUI Verona is a major integrated university hospital in Verona, Italy, combining clinical care with academic research. In H2020, they contributed clinical data and hospital-based expertise to pandemic response studies (COVID-19, SARS-CoV-2) and infectious disease management, including antimicrobial resistance prevention. They also participated in pharmaceutical quality research focused on real-world handling and stability of protein-based drugs in hospital pharmacy settings.

What they specialise in

How they've shifted over time

AOUI Verona's H2020 involvement is concentrated in 2020–2021, largely triggered by the COVID-19 pandemic. Their early projects (EU-RESPONSE, ORCHESTRA) focused squarely on pandemic response — cohort studies, preparedness networks, and epidemiological modeling for SARS-CoV-2. Their later entries (RealHOPE, REVERSE) show a broadening toward hospital pharmacy quality control and antimicrobial resistance, suggesting a shift from emergency pandemic work toward longer-term healthcare system challenges.

Moving from acute pandemic research toward systemic hospital challenges — antimicrobial resistance and pharmaceutical quality — which suggests growing interest in long-term healthcare improvement projects.

How they like to work

AOUI Verona primarily participates as a third party (3 of 4 projects), meaning they typically provide clinical data, patient cohorts, or hospital infrastructure to larger research consortia rather than driving project design. Their one direct participation (RealHOPE) received modest funding (EUR 15,285). With 93 unique partners across 28 countries, they are well-connected despite their supporting role, indicating they are a valued data provider for large-scale European health studies.

Despite limited direct participation, AOUI Verona connects with 93 unique partners across 28 countries — a wide European network built through large pandemic and health consortia. Their reach is broad but driven by the large consortium sizes of their projects rather than active network-building.

What sets them apart

As an integrated university hospital, AOUI Verona offers what pure research institutes cannot: real clinical environments, patient data, and hospital pharmacy operations. Their value lies in providing ground-truth clinical validation — they are where research meets actual patient care. For consortium builders, they represent a reliable Italian clinical site with experience in both infectious disease cohorts and pharmaceutical quality studies.

Highlights from their portfolio

• ORCHESTRA
  Large-scale pan-European COVID-19 cohort study connecting clinical data across countries using federated learning — a flagship pandemic response project.
• REVERSE
  Addresses the critical global challenge of antimicrobial resistance in high-prevalence healthcare settings, combining infection control with cost-effectiveness analysis.
• RealHOPE
  Their only direct participation — a niche but practical project on how protein drugs are actually handled in hospital pharmacies, bridging pharma research and clinical reality.